In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas | Zendy

Federico Gatto | Zendy; Richard A. Feelders | Zendy; Sanne Franck | Zendy; Peter M. van Koetsveld | Zendy; Fadime Dogan | Zendy; Johan M. Kros | Zendy; Sebastian Neggers | Zendy; AartJan van der Lely | Zendy; Steven W. J. Lamberts | Zendy; Diego Ferone | Zendy; Leo J. Hofland | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas

Author(s) -

Federico Gatto,

Richard A. Feelders,

Sanne Franck,

Peter M. van Koetsveld,

Fadime Dogan,

Johan M. Kros,

Sebastian Neggers,

AartJan van der Lely,

Steven W. J. Lamberts,

Diego Ferone,

Leo J. Hofland

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-00135

Subject(s) - acromegaly , pasireotide , octreotide , somatostatin , somatostatin receptor , medicine , endocrinology , adenoma , pituitary adenoma , somatostatin receptor 2 , hormone , growth hormone

First-generation somatostatin analogs (SSAs), such as octreotide (OCT), are the first line medical therapy for acromegaly. Pasireotide (PAS), a newly developed SSA, has shown promising results in the treatment of acromegaly.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research